Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients

Abstract Background Monoclonal antibodies (mAbs) that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are predominantly less effective against Omicron variants. Immunocompromised patients often experience prolonged viral shedding, resulting in an increased risk of viral escape. M...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical infectious diseases Vol. 76; no. 3; pp. 408 - 415
Main Authors:	Gliga, Smaranda, Lübke, Nadine, Killer, Alexander, Gruell, Henning, Walker, Andreas, Dilthey, Alexander T, Thielen, Alexander, Lohr, Carolin, Flaßhove, Charlotte, Krieg, Sarah, Pereira, Joanna Ventura, Seraphin, Tobias Paul, Zaufel, Alex, Däumer, Martin, Orth, Hans-Martin, Feldt, Torsten, Bode, Johannes G, Klein, Florian, Timm, Jörg, Luedde, Tom, Jensen, Björn-Erik Ole
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 08-02-2023
Subjects:	Antibodies, Neutralizing Antibodies, Viral COVID-19 Humans Immunocompromised Host Prospective Studies RNA, Viral SARS-CoV-2 - genetics SARS-CoV-2 immunodeficiency Omicron sotrovimab escape
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Background Monoclonal antibodies (mAbs) that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are predominantly less effective against Omicron variants. Immunocompromised patients often experience prolonged viral shedding, resulting in an increased risk of viral escape. Methods In an observational, prospective cohort, 57 patients infected with Omicron variants who received sotrovimab alone or in combination with remdesivir were followed. The study end points were a decrease in SARS-CoV-2 RNA <106 copies/mL in nasopharyngeal swabs at day 21 and the emergence of escape mutations at days 7, 14, and 21 after sotrovimab administration. All SARS-CoV-2 samples were analyzed using whole-genome sequencing. Individual variants within the quasispecies were subsequently quantified and further characterized using a pseudovirus neutralization assay. Results The majority of patients (43 of 57, 75.4%) were immunodeficient, predominantly due to immunosuppression after organ transplantation or hematologic malignancies. Infections by Omicron/BA.1 comprised 82.5%, while 17.5% were infected by Omicron/BA.2. Twenty-one days after sotrovimab administration, 12 of 43 (27.9%) immunodeficient patients had prolonged viral shedding compared with 1 of 14 (7.1%) immunocompetent patients (P = .011). Viral spike protein mutations, some specific for Omicron (e.g., P337S and/or E340D/V), emerged in 14 of 43 (32.6%) immunodeficient patients, substantially reducing sensitivity to sotrovimab in a pseudovirus neutralization assay. Combination therapy with remdesivir significantly reduced emergence of escape variants. Conclusions Immunocompromised patients face a considerable risk of prolonged viral shedding and emergence of escape mutations after early therapy with sotrovimab. These findings underscore the importance of careful monitoring and the need for dedicated clinical trials in this patient population. Immunodeficient patients had prolonged viral shedding of severe acute respiratory syndrome coronavirus 2 Omicron variants after treatment with sotrovimab. This was associated with rapid selection of escape mutations, which was confirmed in a pseudovirus neutralization assay but was significantly reduced by combination therapy with remdesivir.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/ciac802